secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2026-04-09T23:59:59+00:00
Accession:  0001645113-26-000026
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NovoCure names Dr. Uri Weinberg CMO, adds CHF 5k/month stipend
--------------------------------------------------------------

- Dr. Uri Weinberg, previously Chief Innovation Officer, also appointed Chief Medical Officer effective April 7, 2026.
- Monthly salary increased by CHF 5,000 (gross) for the duration of the CMO assignment.
- Stipend not included in annual incentive payment (AIP); all other terms unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511326000026/0001645113-26-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511326000026/nvcr-20260408.htm
  HTML page:      https://secwatch.observer/filing/0001645113-26-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer